Exocytosis delivers secretory and membrane proteins to the plasma membrane through vesicle fusion, orchestrated by SNARE (Soluble NSF Attachment REceptor) proteins residing on vesicle and target membranes. Trans-SNARE complexes form in a zipper-like ATP-independent manner, pulling membranes into close proximity until they fuse; NSF and α-SNAP subsequently disassemble SNARE complexes. This process is Ca²⁺-dependent via synaptotagmin sensors and can execute within milliseconds, enabling explosive hormone and neurotransmitter release.
Use reconstituted liposome fusion assays with purified SNARE proteins; measure single-vesicle fusion using total internal reflection fluorescence (TIRF) microscopy. Block SNAREs with botulinum toxins to abolish release.
From your study of synaptic vesicle release and protein trafficking, you know that cells package molecules into membrane-bound vesicles and deliver them to specific destinations. Exocytosis is the final step in this delivery — the fusion of a vesicle's membrane with the plasma membrane, releasing its contents outside the cell. The molecular machinery that makes this happen with extraordinary speed and precision is the SNARE complex, and understanding how it works explains everything from insulin secretion to neurotransmitter release.
The key players are two classes of SNARE proteins: v-SNAREs (on the vesicle membrane, such as synaptobrevin/VAMP) and t-SNAREs (on the target plasma membrane, such as syntaxin and SNAP-25). When a vesicle arrives at the plasma membrane, its v-SNARE engages the t-SNAREs in a process that begins at the N-terminal ends of their coiled-coil domains and zippers toward the membrane-anchored C-terminal ends. This progressive zipping of the trans-SNARE complex (so called because the SNAREs span two different membranes) pulls the vesicle and plasma membranes into extremely close apposition — within ~2–3 nm. At this distance, the lipid bilayers become unstable and merge, first forming a hemifusion stalk (where only the outer leaflets mix), then a full fusion pore through which vesicle contents escape. The energy for this mechanical work comes entirely from the formation of the extraordinarily stable four-helix SNARE bundle — no ATP is consumed during the fusion event itself.
The system has two modes of operation. Constitutive exocytosis runs continuously, delivering newly synthesized membrane proteins and lipids to the cell surface without any special trigger. Regulated exocytosis — the kind that drives neurotransmitter release, hormone secretion, and immune cell degranulation — requires a calcium signal. Here, vesicles are docked and primed at the membrane, with partially assembled SNARE complexes held in check by complexin, which acts as a clamp. The calcium sensor synaptotagmin sits on the vesicle membrane with its C2 domains poised to bind Ca²⁺. When an action potential opens voltage-gated calcium channels and local Ca²⁺ concentration spikes, synaptotagmin binds Ca²⁺, undergoes a conformational change, displaces complexin, and drives the final zipping of the SNARE complex. This entire process — from Ca²⁺ entry to vesicle fusion — takes less than a millisecond at a nerve terminal, making it one of the fastest protein-mediated events in biology.
After fusion, the SNARE complex is in its cis configuration — all components now reside in the same membrane, locked in a hyper-stable four-helix bundle that must be disassembled before the SNAREs can be recycled. The AAA+ ATPase NSF (N-ethylmaleimide-sensitive factor), together with its adaptor α-SNAP, pries the complex apart, consuming ATP to unwind the coiled coils. The freed v-SNAREs are recycled back to new vesicles via endocytosis, while t-SNAREs remain on the plasma membrane ready for the next round. The clinical relevance of this machinery is dramatic: botulinum toxins (the most potent known biological toxins) are proteases that cleave specific SNARE proteins — different serotypes cut synaptobrevin, syntaxin, or SNAP-25 — abolishing neurotransmitter release and causing flaccid paralysis. Tetanus toxin similarly cleaves synaptobrevin but in inhibitory interneurons, causing spastic paralysis. These toxins have been repurposed therapeutically as Botox, exploiting the same SNARE-dependent mechanism to silence overactive motor neurons.